Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again

Add two more failures to Merck & Co.’s recent string of Keytruda trial readouts. The once seemingly untouchable immuno-oncology agent appears to have hit a snag in its indication expansion efforts.